ScoreWhy is Fennec Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 5.44% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.26
2
Negative results in Jun 25
- NET SALES(HY) At CAD 25.91 MM has Grown at -41.32%
- NET PROFIT(HY) At CAD -6.03 MM has Grown at -161.99%
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.28%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 79.55%, its profits have fallen by -547.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Fennec Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Fennec Pharmaceuticals, Inc.
6.43%
1.32
67.54%
S&P/TSX 60
23.72%
1.54
14.62%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
123.02%
EBIT Growth (5y)
11.64%
EBIT to Interest (avg)
-11.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.78
Sales to Capital Employed (avg)
1.99
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.19%
ROCE (avg)
0
ROE (avg)
18.98%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-57.05
EV to EBIT
-53.96
EV to EBITDA
-53.96
EV to Capital Employed
-30.29
EV to Sales
6.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET SALES(Q)
Highest at CAD 17.16 MM
RAW MATERIAL COST(Y)
Fallen by -17.8% (YoY
OPERATING PROFIT(Q)
Highest at CAD -0.26 MM
OPERATING PROFIT MARGIN(Q)
Highest at -1.52 %
PRE-TAX PROFIT(Q)
Highest at CAD -0.88 MM
NET PROFIT(Q)
Highest at CAD -0.88 MM
EPS(Q)
Highest at CAD -0.03
-5What is not working for the Company
NET PROFIT(9M)
At CAD -6.91 MM has Grown at -461.56%
Here's what is working for Fennec Pharmaceuticals, Inc.
Net Sales
Highest at CAD 17.16 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Net Sales
At CAD 17.16 MM has Grown at 80.42%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Operating Profit
Highest at CAD -0.26 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CAD MM)
Operating Profit Margin
Highest at -1.52 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CAD -0.88 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CAD MM)
Pre-Tax Profit
At CAD -0.88 MM has Grown at 88.76%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CAD MM)
Net Profit
Highest at CAD -0.88 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CAD MM)
Net Profit
At CAD -0.88 MM has Grown at 88.76%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CAD MM)
EPS
Highest at CAD -0.03
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CAD)
Raw Material Cost
Fallen by -17.8% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
